Compare CYTK & MICC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | MICC |
|---|---|---|
| Founded | 1997 | 2025 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 12.2B |
| IPO Year | 2004 | 2025 |
| Metric | CYTK | MICC |
|---|---|---|
| Price | $54.70 | $20.07 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 4 |
| Target Price | ★ $107.39 | $19.58 |
| AVG Volume (30 Days) | ★ 1.6M | 833.0K |
| Earning Date | 11-04-2026 | 02-12-2027 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,368,000.00 | N/A |
| Revenue This Year | $79.67 | $6.51 |
| Revenue Next Year | $172.23 | $4.35 |
| P/E Ratio | ★ N/A | $28.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $58.25 | $12.94 |
| 52 Week High | $88.31 | $20.69 |
| Indicator | CYTK | MICC |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 60.86 |
| Support Level | $63.96 | $18.83 |
| Resistance Level | $66.93 | $20.69 |
| Average True Range (ATR) | 2.04 | 0.35 |
| MACD | 0.50 | 0.15 |
| Stochastic Oscillator | 86.71 | 91.69 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
The Magnum Ice Cream Co., spun off from Unilever, manufactures and sells a broad portfolio of ice cream brands. The company is a global category leader, operating in 80 countries with around 21% market share. TMICC owns four of the world's five largest ice cream brands: Heartbrand (an umbrella brand with numerous well-known subbrands, which constitutes around 35% of sales), Magnum (23%), Ben & Jerry's (14%), and Cornetto (9%). The business generates about 65% of its revenue in developed markets, with the balance coming from emerging markets.